Hormone receptor positive HER2 negative breast cancer
Not recruitingStudy on Reducing Hormone Therapy Duration with Exemestane, Letrozole, and Anastrozole in Post-Menopausal Women with Low-Risk Hormone-Sensitive Breast Cancer
Study on Reducing Hormone Therapy Duration with Exemestane, Letrozole, and Anastrozole in Post-Menopausal Women with Low-Risk Hormone-Sensitive Breast Cancer
- Disease:Hormone receptor positive HER2 negative breast cancer
- Substances:AnastrozoleExemestane+1
France- Participants:18–64 years · 65+ years
- Substances:Anastrozole
- Sponsor:Unicancer

